SAN

93.2

-0.8%↓

MRK1

114.3

-2.72%↓

SHL.DE

48.29

-1.15%↓

ARGX

516.8

-0.96%↓

FRE

43.29

-0.62%↓

SAN

93.2

-0.8%↓

MRK1

114.3

-2.72%↓

SHL.DE

48.29

-1.15%↓

ARGX

516.8

-0.96%↓

FRE

43.29

-0.62%↓

SAN

93.2

-0.8%↓

MRK1

114.3

-2.72%↓

SHL.DE

48.29

-1.15%↓

ARGX

516.8

-0.96%↓

FRE

43.29

-0.62%↓

SAN

93.2

-0.8%↓

MRK1

114.3

-2.72%↓

SHL.DE

48.29

-1.15%↓

ARGX

516.8

-0.96%↓

FRE

43.29

-0.62%↓

SAN

93.2

-0.8%↓

MRK1

114.3

-2.72%↓

SHL.DE

48.29

-1.15%↓

ARGX

516.8

-0.96%↓

FRE

43.29

-0.62%↓

Search

Vetoquinol SA

Uždarymo kaina

SektoriusSveikatos priežiūra

73.3 -1.74

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

67.9

Max

73.9

Pagrindiniai rodikliai

By Trading Economics

Pajamos

11M

35M

Pardavimai

10M

275M

P/E

Sektoriaus vid.

14.92

54.533

Dividendų pajamingumas

1.22

Pelno marža

12.694

Darbuotojai

2,437

EBITDA

15M

60M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+60.21% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

1.22%

2.41%

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-28M

891M

Ankstesnė atidarymo kaina

75.04

Ankstesnė uždarymo kaina

73.3

Naujienos nuotaikos

By Acuity

50%

50%

187 / 382 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

Vetoquinol SA Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-05-21 23:25; UTC

Karštos akcijos

Stocks to Watch: Navitas Semiconductor, Urban Outfitters, Lumen Technologies, LiveRamp

2025-05-21 21:57; UTC

Įsigijimai, susijungimai, perėmimai

AT&T to Buy Lumen's Mass Markets Fiber Business for $5.75 Billion -- Update

2025-05-21 21:29; UTC

Įsigijimai, susijungimai, perėmimai

Millicom to Acquire Telefónica's Operations in Uruguay

2025-05-21 21:01; UTC

Pagrindinės rinkos jėgos

Nvidia Selects Navitas Semiconductor to Work on Next-Generation 800V HVDC Architecture

2025-05-21 23:49; UTC

Rinkos pokalbiai

Gold Edges Higher on Possible Investor Shift Away From Government Bonds -- Market Talk

2025-05-21 23:37; UTC

Rinkos pokalbiai

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

2025-05-21 23:33; UTC

Įsigijimai, susijungimai, perėmimai

Vigil Neuroscience: Iluzanebart Return to Licensor Amgen to Occur Prior to Closing of Sanofi Deal

2025-05-21 23:32; UTC

Įsigijimai, susijungimai, perėmimai

Vigil Neuroscience Sees Sanofi Deal Strengthening Development Path for Oral Small Molecule TREM2 Agonist Program

2025-05-21 23:32; UTC

Įsigijimai, susijungimai, perėmimai

Vigil Neuroscience: Shareholders to Get Up to $10 a Share in Sanofi Deal >SAN.FR VIGL

2025-05-21 23:32; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

James Hardie's Weak Update Spurs Questions Before AZEK Vote -- Market Talk

2025-05-21 23:31; UTC

Įsigijimai, susijungimai, perėmimai

Samsung Biologics: Remaining Entity to Focus on Contract Development & Manufacturing Organization Business

2025-05-21 23:30; UTC

Įsigijimai, susijungimai, perėmimai

Samsung Biologics: Spun-Off Entity Tentatively Named Samsung Episholdings

2025-05-21 23:30; UTC

Įsigijimai, susijungimai, perėmimai

Samsung Biologics: Separated Business Entity to Focus on R&D Affiliate Samsungbioepis, New Investment

2025-05-21 23:29; UTC

Įsigijimai, susijungimai, perėmimai

Samsung Biologics to Spin off R&D Segment Into Separate Holdings Company

2025-05-21 23:28; UTC

Uždarbis

Singtel to Finance Buybacks Via Excess Capital Generated From Asset Recycling >Z74.SG

2025-05-21 23:27; UTC

Uždarbis

Singtel Sets Up S$2.0B Share-Buyback Program >Z74.SG

2025-05-21 23:26; UTC

Uždarbis

Singtel: Net Rose Due to Exceptional Gain From Partial Divestment of Comcentre Headquarters >Z74.SG

2025-05-21 23:26; UTC

Uždarbis

Singtel FY25 Rev S$14.15B Vs. S$14.13B >Z74.SG

2025-05-21 23:26; UTC

Uždarbis

Singtel FY25 Net S$4.02B Vs. Net S$795.0M >Z74.SG

2025-05-21 23:23; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi: VGL101, Vigil's Second Molecule Program, Isn't Being Acquired

2025-05-21 23:22; UTC

Svarbiausios naujienos

Walmart to Cut 1,500 Corporate Jobs in Restructuring -- WSJ

2025-05-21 23:22; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi Sees No Effect From Vigil Deal on 2025 Outlook >SAN.FR

2025-05-21 23:20; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi: Vigil Deal Enhances Early-Stage Pipeline, Includes VG-3927, Which Will Be Evaluated in Alzheimer's Disease Study

2025-05-21 23:18; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi to Buy Vigil Neuroscience for $8 a Share at Closing >SAN.FR VIGL

2025-05-21 23:04; UTC

Svarbiausios naujienos

EV Owners Face Annual Fee Under Proposed Tax Bill -- Barrons.com

2025-05-21 21:46; UTC

Svarbiausios naujienos

NBCUniversal Bids for MLB Rights That Were Dropped by ESPN -- WSJ

2025-05-21 21:42; UTC

Svarbiausios naujienos
Įsigijimai, susijungimai, perėmimai

AT&T to Buy Lumen's Mass Markets Fiber Business for $5.75B -- Update

2025-05-21 21:14; UTC

Įsigijimai, susijungimai, perėmimai

Millicom to Acquire Telefónica's Ops in Uruguay

2025-05-21 21:07; UTC

Svarbiausios naujienos

NBCUniversal Bids for Major League Baseball Rights ESPN Dropped, Sources Say -- WSJ

2025-05-21 21:06; UTC

Įsigijimai, susijungimai, perėmimai

Uber Stock Is Dropping. Blame Elon Musk and Tesla. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Vetoquinol SA Prognozė

Kainos tikslas

By TipRanks

60.21% į viršų

12 mėnesių prognozė

Vidutinis 120 EUR  60.21%

Aukščiausias 120 EUR

Žemiausias 120 EUR

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Vetoquinol SA kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

1 ratings

1

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

72.6 / 75.1Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bearish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

187 / 382 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Vetoquinol SA

Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.